How Long Does LL-37 Stay in Your System? What the Literature Reports

Answer first: what the evidence set does and does not contain

People asking how long LL-37 “stays in the system” are usually asking a pharmacokinetic question: half-life, time to clearance, and whether a test could pick it up. The peer-reviewed papers assembled for this page do not answer that question. They are mechanistic studies — bacterial killing assays, cell-culture experiments, mouse models and protein-binding work — and none of them stated a plasma half-life, an elimination rate or a concentration-time curve for LL-37 in humans. For example, the study of LL-37 against Staphylococcus aureus biofilms reported bactericidal activity in an in vitro system rather than any blood-level measurement (PMID 31170191), and the receptor study in group A streptococcal infection examined LL-37-mediated activation of host receptors rather than drug disposition (PMID 33657368).

That absence is itself the honest answer. Anything stated below about half-lives in general is general peptide pharmacology, clearly labelled as such, and is not a finding about LL-37 from the cited papers. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a specific substance, test or medical condition.

One complication unique to LL-37: the body makes it

LL-37 is the mature peptide form of human cathelicidin (hCAP-18). Unlike a purely synthetic research compound, it is an endogenous human peptide, so a measurable level in blood, mucus or tissue does not by itself indicate that anything was administered. Its production is also regulated: researchers described LL-37 as a vitamin D-inducible antimicrobial peptide when they reported that it binds SARS-CoV-2 Spike and the accessory proteins ORF7a and ORF8 (PMID 41064641). Induction means endogenous levels are not fixed, which is a different variable from elimination and one that any interpretation of a measured level has to account for.

Animal work in the same family reinforces that cathelicidin activity is tied to tissue biology rather than a single circulating pool: a 2025 study reported that cathelicidin regulated goblet cell mucus secretion and mucus-associated proteins in Citrobacter rodentium-induced colitis (PMID 40735968). Findings in rodent colitis describe mouse biology; they are not human pharmacokinetics.

Where LL-37 has actually been measured or located in these studies

Instead of blood-level time courses, the verified literature describes compartments — the places LL-37 has been found, bound or taken up. Those locations matter for anyone trying to reason about persistence, because a peptide bound to a protein, a membrane or the inside of a cell is not behaving like free peptide in plasma.

• Bound to a plasma lipoprotein component. Researchers reported that a cathelicidin LL-37–ApoB-100 interaction promoted LDL clearance and attenuated cholesterol accumulation in the liver (PMID 40971038). Binding to a circulating lipoprotein protein is directly relevant to distribution, although the study reported a lipid-handling outcome, not a half-life.
• Inside host cells. A 2020 study reported that LL-37-induced autophagy contributed to the elimination of live Porphyromonas gingivalis internalized in keratinocytes (PMID 33178622), an intracellular setting rather than a circulating one.
• Absent from a compartment where it was looked for. A 2025 study reported that Legionella pneumophila-induced neutrophil extracellular traps did not bear LL-37 peptides (PMID 41156758). This is a useful reminder that detection depends entirely on which compartment is sampled and which assay is used.
• In macrophage culture. Researchers reported that synthetic cathelicidin LL-37 reduced Mycobacterium avium subsp. paratuberculosis internalization and pro-inflammatory cytokines in macrophages (PMID 31478135) — synthetic peptide added to cells in a dish, with no systemic exposure to track.

Study-by-study: which papers are LL-37-specific, and what endpoint each used

The table separates papers that name LL-37 or cathelicidin in their stated scope from papers in this set that do not, so that nothing is read as compound-specific evidence when it is not. No row reports a pharmacokinetic endpoint.

General peptide pharmacology (not LL-37 data)

Because no half-life for LL-37 appears in the papers above, the only remaining framework is general peptide pharmacology, which is taught in pharmacology curricula rather than derived from the citations on this page. In broad terms, linear peptides made of standard L-amino acids are subject to proteolysis by circulating and tissue peptidases, renal filtration and handling of small fragments, receptor- or target-mediated uptake, and binding to plasma proteins and cell membranes. These processes are why unmodified peptides typically show much shorter plasma persistence than small-molecule drugs, and why the length of time a peptide remains biologically relevant in a tissue can differ from how long it remains measurable in blood.

None of those general statements should be read as an LL-37 number. A category-level expectation is not a measurement. For a broader treatment of how peptide clearance is studied across compounds, see the companion guide at how long peptides stay in the system.

Factors that plausibly shift exposure — and how the evidence maps onto them

• Endogenous induction. LL-37 was described as vitamin D-inducible in the SARS-CoV-2 protein-binding study (PMID 41064641), meaning baseline levels are not static.
• Protein binding. The reported LL-37–ApoB-100 interaction shows the peptide can associate with a lipoprotein component in circulation (PMID 40971038), which in general pharmacology terms changes free versus bound fractions.
• Cellular uptake. Internalization-related activity was reported in keratinocytes (PMID 33178622) and macrophages (PMID 31478135), and uptake removes peptide from extracellular space.
• Surface and membrane binding. Physical-chemistry work on membrane interactions of nanoparticles illustrates how surfaces can engage lipid membranes in vitro (PMID 28682360), a general principle relevant to assay behaviour rather than an LL-37 clearance measurement.
• Formulation and delivery vehicles. Carrier systems change where a payload goes; the nanodecoy platform for periodontitis is an example of such engineering (PMID 40228155), though that study is not an LL-37 pharmacokinetic report.

Detectability and drug testing: what is and is not screened

Stated plainly: standard workplace, clinical toxicology and roadside drug panels are built to detect specific classes of small molecules — amphetamines, cannabinoids, opioids, cocaine metabolites, benzodiazepines, alcohol and similar analytes. They do not include LL-37, and a routine immunoassay panel would not report it. Detecting LL-37 requires purpose-built methods such as peptide-specific immunoassays, antibody staining or mass spectrometry, which is how the verified papers located or failed to locate the peptide in defined compartments — for instance the report that Legionella pneumophila-induced NETs did not bear LL-37 peptides used compartment-specific detection rather than a generic screen (PMID 41156758).

Two further points matter for interpretation. First, because LL-37 is an endogenous human peptide, a positive measurement is not inherently evidence of exogenous administration; distinguishing endogenous from administered peptide is a separate analytical problem. Second, sport anti-doping rules and laboratory testing menus are set by individual organisations, change over time, and are outside the scope of the papers cited here; this page does not summarise them and nothing here is legal advice.

Adverse Events and Tolerability: What Studies Report

The verified papers on this page are in vitro, cell-culture and animal studies and did not report human adverse-event data, tolerability outcomes or safety monitoring in people. The antimicrobial work reported bacterial killing endpoints in biofilm systems (PMID 31170191) and the macrophage study reported changes in internalization and pro-inflammatory cytokines in cultured cells (PMID 31478135); neither design can characterise safety in humans. Because no dosing study in humans appears in this evidence set, no dose, exposure duration or adverse-event rate is stated on this page.

How to read persistence claims you may encounter

1. Check the species and the system. A mouse colitis model reported cathelicidin effects on mucus secretion (PMID 40735968); that is not a human blood half-life.
2. Check the endpoint. “Clearance” in the LL-37–ApoB-100 paper referred to LDL clearance (PMID 40971038), not clearance of the peptide itself — an easy phrase to misread.
3. Check whether the compound is even in the paper. The rosacea laser study (PMID 41123652) and the SLIT2 innate-immunity study (PMID 37773612) are frequently discussed alongside cathelicidin biology, but their stated scopes are a laser intervention and a chemorepellent protein respectively.
4. Treat category-level pharmacology as a framework, not a number.

Related reading

• LL-37: what the literature covers
• How long peptides stay in the system

References

• Engineered Macrophage Membrane-Camouflaged Nanodecoys Reshape the Infectious Microenvironment for Efficient Periodontitis Treatment (ACS Nano, 2025)
• Legionella pneumophila-Induced NETs Do Not Bear LL-37 Peptides (Microorganisms, 2025)
• Cathelicidin regulates goblet cell mucus secretion and mucus-associated proteins in Citrobacter rodentium-induced colitis (Gut Microbes, 2025)
• Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver (Science China Life Sciences, 2026)
• Long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser alleviates rosacea by improving lymphatic vessel dysfunction (Inflammation Research, 2025)
• Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8 (Frontiers in Cellular and Infection Microbiology, 2025)
• Membrane interactions and antimicrobial effects of layered double hydroxide nanoparticles (Physical Chemistry Chemical Physics, 2017)
• LL-37-Induced Autophagy Contributed to the Elimination of Live Porphyromonas gingivalis Internalized in Keratinocytes (Frontiers in Cellular and Infection Microbiology, 2020)
• Synthetic cathelicidin LL-37 reduces Mycobacterium avium subsp. paratuberculosis internalization and pro-inflammatory cytokines in macrophages (Cell and Tissue Research, 2020)
• The chemorepellent, SLIT2, bolsters innate immunity against Staphylococcus aureus (eLife, 2023)
• LL-37-mediated activation of host receptors is critical for defense against group A streptococcal infection (Cell Reports, 2021)
• Antimicrobial peptide LL-37 is bactericidal against Staphylococcus aureus biofilms (PLoS One, 2019)